Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313

Daniel O. Persky, Thomas P Miller, Joseph M. Unger, Catherine S Perry, Soham D Puvvada, B. Dino Stea, Oliver W. Press, Louis S. Constine, Kevin P. Barton, Jonathan W. Friedberg, Michael LeBlanc, Richard I. Fisher

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

In the S0313 trial, we evaluated the impact of adding ibritumomab tiuxetan consolidation to 3 cycles of standard cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy plus involved field radiotherapy (IFRT) in patients with limited-stage aggressive B-cell non-Hodgkin lymphoma (LD-NHL). Patients with at least 1 stage-modified adverse risk factor (nonbulky stage II, age >60 years, elevated lactate dehydrogenase, or World Health Organization performance status of 2) were treated with CHOPon days 1, 22, and 43, followed 3 weeks later by 40 to 50 Gy of IFRT. An ibritumomab tiuxetan regimen was initiated 3 to 6 weeks following IFRT. Forty-six patients were registered and eligible, with median follow-up of 7.3 years. The progression-free survival estimate is89%at 2 years,82%at 5 years, and75% at 7 years. The overall survival estimate is 91% at 2 years, 87% at 5 years, and 82% at 7 years. Grade 4 adverse events occurring more than once included neutropenia (8), leukopenia (5), and lymphopenia (2). Febrile neutropenia was observed in 4 patients. No cases of treatment-related myeloid neoplasms were noted. In conclusion, patients with high-risk LD-NHL treated with 3 cycles of CHOP plus IFRT followed by ibritumomab tiuxetan consolidation had outcomes that compare favorably to our historical experience. The clinical trial was registered at www.clinicaltrials.gov as #NCT00070018.

Original languageEnglish (US)
Pages (from-to)236-241
Number of pages6
JournalBlood
Volume125
Issue number2
DOIs
StatePublished - Aug 8 2015

Fingerprint

Radiotherapy
B-Cell Lymphoma
Consolidation
Cells
Non-Hodgkin's Lymphoma
Chemotherapy
Vincristine
Prednisone
Febrile Neutropenia
L-Lactate Dehydrogenase
Lymphopenia
Second Primary Neoplasms
Doxorubicin
Cyclophosphamide
Leukopenia
Neutropenia
Health
Disease-Free Survival
Clinical Trials
Drug Therapy

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma : SWOG S0313. / Persky, Daniel O.; Miller, Thomas P; Unger, Joseph M.; Perry, Catherine S; Puvvada, Soham D; Dino Stea, B.; Press, Oliver W.; Constine, Louis S.; Barton, Kevin P.; Friedberg, Jonathan W.; LeBlanc, Michael; Fisher, Richard I.

In: Blood, Vol. 125, No. 2, 08.08.2015, p. 236-241.

Research output: Contribution to journalArticle

Persky, DO, Miller, TP, Unger, JM, Perry, CS, Puvvada, SD, Dino Stea, B, Press, OW, Constine, LS, Barton, KP, Friedberg, JW, LeBlanc, M & Fisher, RI 2015, 'Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313', Blood, vol. 125, no. 2, pp. 236-241. https://doi.org/10.1182/blood-2014-06-584623
Persky, Daniel O. ; Miller, Thomas P ; Unger, Joseph M. ; Perry, Catherine S ; Puvvada, Soham D ; Dino Stea, B. ; Press, Oliver W. ; Constine, Louis S. ; Barton, Kevin P. ; Friedberg, Jonathan W. ; LeBlanc, Michael ; Fisher, Richard I. / Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma : SWOG S0313. In: Blood. 2015 ; Vol. 125, No. 2. pp. 236-241.
@article{38fd0e0d1aae4ab0ac05271ab1521142,
title = "Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313",
abstract = "In the S0313 trial, we evaluated the impact of adding ibritumomab tiuxetan consolidation to 3 cycles of standard cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy plus involved field radiotherapy (IFRT) in patients with limited-stage aggressive B-cell non-Hodgkin lymphoma (LD-NHL). Patients with at least 1 stage-modified adverse risk factor (nonbulky stage II, age >60 years, elevated lactate dehydrogenase, or World Health Organization performance status of 2) were treated with CHOPon days 1, 22, and 43, followed 3 weeks later by 40 to 50 Gy of IFRT. An ibritumomab tiuxetan regimen was initiated 3 to 6 weeks following IFRT. Forty-six patients were registered and eligible, with median follow-up of 7.3 years. The progression-free survival estimate is89{\%}at 2 years,82{\%}at 5 years, and75{\%} at 7 years. The overall survival estimate is 91{\%} at 2 years, 87{\%} at 5 years, and 82{\%} at 7 years. Grade 4 adverse events occurring more than once included neutropenia (8), leukopenia (5), and lymphopenia (2). Febrile neutropenia was observed in 4 patients. No cases of treatment-related myeloid neoplasms were noted. In conclusion, patients with high-risk LD-NHL treated with 3 cycles of CHOP plus IFRT followed by ibritumomab tiuxetan consolidation had outcomes that compare favorably to our historical experience. The clinical trial was registered at www.clinicaltrials.gov as #NCT00070018.",
author = "Persky, {Daniel O.} and Miller, {Thomas P} and Unger, {Joseph M.} and Perry, {Catherine S} and Puvvada, {Soham D} and {Dino Stea}, B. and Press, {Oliver W.} and Constine, {Louis S.} and Barton, {Kevin P.} and Friedberg, {Jonathan W.} and Michael LeBlanc and Fisher, {Richard I.}",
year = "2015",
month = "8",
day = "8",
doi = "10.1182/blood-2014-06-584623",
language = "English (US)",
volume = "125",
pages = "236--241",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "2",

}

TY - JOUR

T1 - Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma

T2 - SWOG S0313

AU - Persky, Daniel O.

AU - Miller, Thomas P

AU - Unger, Joseph M.

AU - Perry, Catherine S

AU - Puvvada, Soham D

AU - Dino Stea, B.

AU - Press, Oliver W.

AU - Constine, Louis S.

AU - Barton, Kevin P.

AU - Friedberg, Jonathan W.

AU - LeBlanc, Michael

AU - Fisher, Richard I.

PY - 2015/8/8

Y1 - 2015/8/8

N2 - In the S0313 trial, we evaluated the impact of adding ibritumomab tiuxetan consolidation to 3 cycles of standard cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy plus involved field radiotherapy (IFRT) in patients with limited-stage aggressive B-cell non-Hodgkin lymphoma (LD-NHL). Patients with at least 1 stage-modified adverse risk factor (nonbulky stage II, age >60 years, elevated lactate dehydrogenase, or World Health Organization performance status of 2) were treated with CHOPon days 1, 22, and 43, followed 3 weeks later by 40 to 50 Gy of IFRT. An ibritumomab tiuxetan regimen was initiated 3 to 6 weeks following IFRT. Forty-six patients were registered and eligible, with median follow-up of 7.3 years. The progression-free survival estimate is89%at 2 years,82%at 5 years, and75% at 7 years. The overall survival estimate is 91% at 2 years, 87% at 5 years, and 82% at 7 years. Grade 4 adverse events occurring more than once included neutropenia (8), leukopenia (5), and lymphopenia (2). Febrile neutropenia was observed in 4 patients. No cases of treatment-related myeloid neoplasms were noted. In conclusion, patients with high-risk LD-NHL treated with 3 cycles of CHOP plus IFRT followed by ibritumomab tiuxetan consolidation had outcomes that compare favorably to our historical experience. The clinical trial was registered at www.clinicaltrials.gov as #NCT00070018.

AB - In the S0313 trial, we evaluated the impact of adding ibritumomab tiuxetan consolidation to 3 cycles of standard cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy plus involved field radiotherapy (IFRT) in patients with limited-stage aggressive B-cell non-Hodgkin lymphoma (LD-NHL). Patients with at least 1 stage-modified adverse risk factor (nonbulky stage II, age >60 years, elevated lactate dehydrogenase, or World Health Organization performance status of 2) were treated with CHOPon days 1, 22, and 43, followed 3 weeks later by 40 to 50 Gy of IFRT. An ibritumomab tiuxetan regimen was initiated 3 to 6 weeks following IFRT. Forty-six patients were registered and eligible, with median follow-up of 7.3 years. The progression-free survival estimate is89%at 2 years,82%at 5 years, and75% at 7 years. The overall survival estimate is 91% at 2 years, 87% at 5 years, and 82% at 7 years. Grade 4 adverse events occurring more than once included neutropenia (8), leukopenia (5), and lymphopenia (2). Febrile neutropenia was observed in 4 patients. No cases of treatment-related myeloid neoplasms were noted. In conclusion, patients with high-risk LD-NHL treated with 3 cycles of CHOP plus IFRT followed by ibritumomab tiuxetan consolidation had outcomes that compare favorably to our historical experience. The clinical trial was registered at www.clinicaltrials.gov as #NCT00070018.

UR - http://www.scopus.com/inward/record.url?scp=84921058911&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921058911&partnerID=8YFLogxK

U2 - 10.1182/blood-2014-06-584623

DO - 10.1182/blood-2014-06-584623

M3 - Article

C2 - 25395425

AN - SCOPUS:84921058911

VL - 125

SP - 236

EP - 241

JO - Blood

JF - Blood

SN - 0006-4971

IS - 2

ER -